A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Small Cell Lung Cancer

In brief

The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).

Key facts

Study ID

NCT03026166

Run by

AbbVie

People needed

42

Starts

2017-03-30

Expected to finish

2019-07-03

Last updated by the study team

2020-07-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC) with progressive disease after at least one platinum-based chemotherapeutic regimen and with evaluable or measurable disease
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate hematologic, hepatic, and renal function

You may not qualify if…

• Has active, known, or suspected autoimmune disease
• Had prior exposure to an immuno-oncology or pyrrolobenzodiazepine (PBD)-based drug

Where it is running

• Ucsd /Id# 161030 — La Jolla, California, United States
• Florida Hospital /ID# 161017 — Orlando, Florida, United States
• University Cancer & Blood Cent /ID# 161028 — Athens, Georgia, United States
• University of Chicago /ID# 161006 — Chicago, Illinois, United States
• The University of Kansas Clini /ID# 162915 — Fairway, Kansas, United States
• Washington University-School of Medicine /ID# 161011 — St Louis, Missouri, United States
• Rutgers Cancer Institute of NJ /ID# 161032 — New Brunswick, New Jersey, United States
• Memorial Sloan Kettering Cancer Center /ID# 161010 — New York, New York, United States
• Duke University Medical Center /ID# 161009 — Durham, North Carolina, United States
• Oregon Health and Science University /ID# 161029 — Portland, Oregon, United States
• Medical University of South Carolina /ID# 161007 — Charleston, South Carolina, United States
• Tennessee Oncology, PLLC /ID# 161012 — Nashville, Tennessee, United States
• Vanderbilt University Med Ctr /ID# 162916 — Nashville, Tennessee, United States
• Virginia Cancer Institute /ID# 161025 — Richmond, Virginia, United States
• University of Wisconsin Clinic /ID# 161013 — Madison, Wisconsin, United States
• CHU de Besancon - Jean Minjoz /ID# 165173 — Besançon, Doubs, France
• Centre Oscar Lambret /ID# 165169 — Lille, Hauts-de-France, France
• Institut Gustave Roussy /ID# 165168 — Villejuif, Val-de-Marne, France
• Institut Sainte Catherine /ID# 165172 — Avignon, France
• CHRU de Brest - Hospital Morva /ID# 165170 — Brest, France
• Hopital La Timone /ID# 165171 — Marseille, France
• KH Martha-Maria Halle Dolau /ID# 165180 — Halle, Saxony-Anhalt, Germany
• Asklepios Fachkliniken M. Gaut /ID# 165183 — Gauting, Germany
• Lungen Clinic Grosshansdorf /ID# 165182 — Großhansdorf, Germany
• Lungenfachklinik Immenhausen /ID# 165181 — Immenhausen, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.